GlobeNewswire

HUVEPHARMA STOPS IPO PROCESS

Share

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR
INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN
VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

HUVEPHARMASTOPS IPO PROCESS

Amsterdam, the Netherlands, 30 June 2021 – Huvepharma B.V. (the “Company”) and together with its consolidated subsidiaries (the “Group”), a leading global livestock animal health company with strong positions in the veterinary and feed additives segments, today announced that the Group and its sole shareholder, Advance Properties OOD (the “Selling Shareholder”), have decided to stop the proposed IPO on Euronext Amsterdam.

Kiril Domuschiev, President and CEO of Huvepharma said: "Our business is highly profitable and cash-generative and growing faster than its peers1, with its growth supported bydemand for high-quality animal protein growing globally. Throughout the process we have much appreciated the intensive interaction with all the reputable institutional investors. It became evident to me from their feedback during the process that the Company’s current and medium-term growth trajectory will be best supported by staying private for the time being, preserving the Group’s agility and entrepreneurial culture.However, we might revisit the IPO project at a later date in the future."

With the support of its management, employees, clients and shareholder, Huvepharma therefore remains committed to pursuing its successful global development strategy as a private company in the medium-term.

Huvepharma would like to thank all investors, analysts and journalists connected to the process for their interest in the Group and for their valuable feedback.

HUVEPHARMA HIGHLIGHTS

  • The Company is the fastest-growing global livestock animal health company (in terms of sales growth) with a focus on developing, manufacturing and marketing animal and human health and nutrition products2. The global animal health market generated annual revenue of circa $33bn in 2019, of which circa $20bn, or 60% of the market, represents livestock animals. The Company is the 6th largest company by revenue in the livestock health industry (including livestock animal vaccine products), and the 2nd largest by revenue in swine and poultry animal health (excluding vaccines). With more than half a century of expertise, the Company is dedicated to offering high quality products and services to help customers improve livestock animal health.
  • Based in the European Union and with main production sites in Italy, France, Bulgaria and the United States across a total of 13 locations, the Company is highly self-sufficient; more than 95% of its finished products are produced internally.
  • The segment of livestock animals in which the Company operates (poultry, swine, cattle, sheep and aqua) is expected to grow at a CAGR of 5% for the years 2019 to 2024 (in nominal terms) according to Vetnosis - a faster rate than other animal health areas, such as companion animals, which is expected to have a CAGR of 2.5% over the same period (according to Vetnosis). The growth is mainly driven by three factors: an increase in the global population; a larger and growing middle-class in developing countries demanding more high-quality animal proteins; and increased food safety concerns and demand for higher quality standards resulting in increasing demand for better quality meat. Though there is a growing trend of vegan alternatives in developed markets, the Group expects that the impact of this trend on the overall mid- to long-term demand for food animal products will be limited.
  • The Company’s leadership lies in its operational model that combines an exclusive focus on key livestock growth areas with best-in-class reliable and tailored products made to the highest health and safety standards, all based on customer proximity and service models that foster trust and loyalty.
  • Over the last three years Huvepharma has consistently grown faster than the market in terms of sales growth. This resulted in revenues of €588m and an EBITDA of €167m with an EBITDA margin of 28.4% in 2020.

MEDIA CONTACTS

Huvepharma B.V.
Alain Kanora DVM Diplomate ECPHM
Phone: +32 3 292 8306
M+32 473 900 426
E Alain.kanora@huvepharma.com

Holland – SPJ/AMO
Kees Jongsma                                              Fons van Lith
M +31 6 54 798 253                                       M +31 651 314 952;
E cjongsma@spj.nl                                        E fvanlith@spj.nl

United Kingdom – Maitland/AMO
David Sturken
M +44-7990595913
E dsturken@maitland.co.uk

DISCLAIMERS

This press release contains information within the meaning of Article 7(1) of the European Market Abuse Regulation (596/2014)
----------------------------------------------------------------------

The contents of this announcement have been prepared by and are the sole responsibility of the Company.

This announcement may include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements may be identified by the use of forward-looking terminology, including the terms "plans", "targets", "aims", "believes", "expects", "anticipates", "intends", "estimates", "will", "might", "continues", "should", "continue", "positioned", "ongoing" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that the predictions, forecasts, projections, guidance and other forward-looking statements will not be achieved. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law.

This announcement and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of any securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful and this announcement and the information contained herein are not for distribution or release, directly or indirectly, in or into such jurisdictions.

None of J.P. Morgan AG, BNP Paribas, Citigroup Global Markets Europe AG, ING Bank N.V., UniCredit Bank AG, Milan Branch, Coöperatieve Rabobank U.A., KBC Securities NV and Raiffeisen Bank International AGor any of their respective directors, officers, employees, advisers or agents accepts any responsibility or liability whatsoever for or makes any representation or warranty, express or implied, as to the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company, its subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this announcement or its contents or otherwise arising in connection therewith.


1 2015-19 reported livestock sales growth of competitors compiled by Vetnosis
2 2015-19 reported livestock sales growth of competitors compiled by Vetnosis

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Idorsia announces financial results for the first half 2021 – Building momentum towards becoming a fully-fledged biopharmaceutical company27.7.2021 07:01:34 CEST | Press release

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 27, 2021 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2021. Business highlights Daridorexant for the treatment of insomnia under review with US FDA, EMA, and SwissmedicNine scientific presentations for daridorexant shared at SLEEP 2021Ponesimod to treat relapsing forms of multiple sclerosis was approved by the US FDA and the European Commission, Idorsia receives first income from the revenue-sharing agreement in respect to ponesimodClazosentan NDA for the treatment of cerebral vasospasm post aneurysmal subarachnoid hemorrhage (aSAH) submitted to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in March 2021“SOS-AMI” Phase 3 registration study with selatogrel in suspected acute myocardial infarction (AMI) initiated in June 2021Phase 2 study with ACT-539313 for binge eating disorder initiated in March 2021Results for MODIFY Phase 3 study with lucerastat for Fabry

Hyloris to Report 2021 Half-Year Results on 4 August 202127.7.2021 07:00:00 CEST | Press release

Liège, Belgium – 27 July 2021 –Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it will host a conference call and audio webcast on Wednesday, 4 August 2021 at 3:00 pm CEST (9:00 am EST) to present its half-year 2021 financial results and to provide a business update. The presentation will be followed by a live Q&A session. The webcast may be accessed on the Events page of the company’s website or by clicking here. To participate in the Q&A session of the conference call, please dial one of the following numbers, ten minutes prior to the start of the live webcast: Belgium +32 2 79 338 47 France +33 1 70 700 781 Netherlands + 31 20 795 6614 United Kingdom +44 2071 928 338 United States +1 646 741 3167 Confirmation code 2687826 Following the call, a replay of the webcast will be available on the events page of the Hyloris website. About Hyloris Phar

Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor27.7.2021 07:00:00 CEST | Press release

Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation)i; agent is being studied in an area of significant unmet need Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Jersey City, N.J., Geneva, Switzerland, July 27, 2021 - Organon (NYSE: OGN), a global women’s health company and ObsEva (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company dedicated to improving women’s reproductive health, today announced that the companies have entered into an agreement whereby Organon will license the global development, manufacturing and commercial rights to ebopiprant (OBE022). Ebopiprant is an investigational, orally active, selective prostaglandin F2α (PGF2α) receptor antagonist being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions. If approved, it has potential to be a first-in-class innovation for this common and serious condition with no approved therapies for acute treatme

Wereldhave N.V.: Results H1 202127.7.2021 07:00:00 CEST | Press release

Key items Major step in phasing out France: sold four out of six French assets for € 305mBenelux disposal program finalized, Koningshoek sold above book value LTV down to 46% - pro-forma for four asset French disposal 42%Dutch valuations stabilizing for the first time in nine valuation roundsAs a result of disposals, outlook 2021 direct result now at € 1.75 - 1.85 per shareOutlook direct result 2022 reiterated at € 1.40 - € 1.50 per share; to be followed by 4 - 6% annual growthDividend guidance 2021 minimum € 1.00 per share Attachment Wereldhave pr 2021-H1 - vFINAL

Leasinvest Real Estate SA: Publication of a transparency notification26.7.2021 18:00:00 CEST | Press release

PUBLICATION OF A TRANSPARENCY NOTIFICATION IN ACCORDANCE WITH THE LAW OF 02/05/2007 ON THE DISCLOSURE OF IMPORTANT PARTICIPATIONS A notification of 26 July 2021 issued by AG Insurance, shows that both a passive threshold overrun and a drop below the minimum threshold took place, following the introduction of the double voting rights and a capital increase by contribution in kind from a/o Extensa Group, as approved at the extraordinary general meeting of Leasinvest Real Estate on 19 July 2021. The total number of voting rights of AG Insurance in Leasinvest Real Estate has therefore decreased to 2.58% of the voting rights in Leasinvest Real Estate NV (hereinafter the "Company”). The notification comprises the following information: REASON FOR THE NOTIFICATION: Passive threshold overrun - Drop below the minimum threshold NOTIFICATION: by the parent company or controlling person. PERSON(S) SUBJECT TO THE NOTIFICATION REQUIREMENT Name and legal formAddress Ageas SA/NV Rue du Marquis 1, 1000

PRESS RELEASE: BIGBEN: Q1 2021/22 Sales26.7.2021 17:50:00 CEST | Press release

Bigben Press release Lesquin, 26 July 2021 18:00 hrs Q1 2021/22 Sales: 56.7 M€ (+2.8%) High sales historyforNacon Gaming Favourable base effect for Audio-Telco Confirmation of FY 2021/22 and FY 2022/23 targets IFRS – M€ Sales 2021/2022 2020/2021 Change 1st Quarter Nacon Gaming Bigben Audio-Telco 56.7 33.7 23.0 55.2 38.0 17.2 +2.8% -11.3% +33.9% Non audited data In Q1 FY 2021/22 (April 1 to June 30, 2021), Bigben posted sales of €56.7 million, an increase of 2.8%, driven by Audio-Telco, which benefited from a favourable comparison basis, unlike the Nacon Gaming business unit, demonstrating the benefit from being present across several markets. NACON GAMING In Q1 2021/22, Nacon achieved sales of 33.7 M€, down 11.3% on Q1 2020/2021. Despite an unfavourable comparison basis, the back catalogue showed a positive momentum. Games: The segment posted sales of 12.2 M€, down 16.0% compared with Q1 2020/21, whose back catalogue sales had been boosted by 340% by lockdown. The back catalogue demons

PRESS RELEASE: NACON: Q1 2021/22 Sales26.7.2021 17:45:00 CEST | Press release

Press release Lesquin, 26 July 2021 18 :00hrs Q1 2021/22 Sales : 33.7 M€(-11.3%) High comparison basisBack catalogue résilience Confirmation ofFY 2021/22 and FY 2022/23targets IFRS – M€ Sales Non audited data 2021/2022 2020/2021 Change 1st Quarter Games Accessories Others(1) 33.7 12.2 20.6 0.9 38.0 14.5 22.5 0.9 - 11.3% -16.0% -8.8% + 0.5% (1)Mobile and Audio sales. In Q1 2021/22 (from 1 April to 30 June 2021), Nacon achieved sales of 33.7 M€, down 11.3% compared to Q1 2020/2021. Despite an unfavourable comparison basis, the back catalogue showed a positive momentum. GAMES The video games business posted sales of 12.2 M€, down 16.0% compared with Q1 2020/21, when back catalogue sales were boosted 340% by lockdown. However the good performance of the back catalogue demonstrated its resilience with sales of 9.2 M€ against 10.8 M€ in Q1 2020/21 during the first lockdown, to be compared with 2.4 M€ in Q1 2019/20. The Roguebook (81% positive reviews on Steam) and Pro Cycling Management / To